Groundbreaking: First-Ever HCC RAF Score Accessible Through REST API
First-Ever HCC RAF Score Accessible Through REST API
Check Now
Image depicting the concept of elevating provider support and enhancing concurrent coding for risk adjustment in healthcare.
Elevate Provider Support:
Enhance Your Concurrent Coding
for Risk Adjustment
Check Now
ICD10 PCS Codes X XW XW0 XW03

ICD-10-CM Diagnosis Code

Peripheral Vein(XW03)

  • XW03 Peripheral Vein
    • XW033 Percutaneous
      • XW0330 Spesolimab Monoclonal Antibody
        • XW03306 New Technology Group 6
        • XW03308 New Technology Group 8
      • XW0332 Nerinitide
        • XW03326 New Technology Group 6
      • XW0333 Bentracimab, Ticagrelor Reversal Agent
        • XW0333A New Technology Group 10
      • XW0334 Cefepime-taniborbactam Anti-infective
      • XW0335 Ceftobiprole Medocaril Anti-infective
        • XW03357 New Technology Group 7
        • XW03358 New Technology Group 8
        • XW0335A New Technology Group 10
      • XW0336 Afamitresgene Autoleucel Immunotherapy
        • XW03366 New Technology Group 6
        • XW03367 New Technology Group 7
        • XW03368 New Technology Group 8
      • XW0337 Tabelecleucel Immunotherapy
        • XW03372 New Technology Group 2
        • XW03377 New Technology Group 7
        • XW03378 New Technology Group 8
      • XW0338 Obecabtagene Autoleucel
        • XW03387 New Technology Group 7
        • XW03388 New Technology Group 8
        • XW0338A New Technology Group 10
      • XW0339 Odronextamab Antineoplastic
        • XW03396 New Technology Group 6
        • XW03398 New Technology Group 8
        • XW0339A New Technology Group 10
      • XW033A Ciltacabtagene Autoleucel
        • XW033A6 New Technology Group 6
        • XW033A7 New Technology Group 7
      • XW033B Orca-T Allogeneic T-cell Immunotherapy
        • XW033B3 New Technology Group 3
        • XW033B6 New Technology Group 6
        • XW033B7 New Technology Group 7
        • XW033BA New Technology Group 10
      • XW033C Zanidatamab Antineoplastic
        • XW033C6 New Technology Group 6
        • XW033C7 New Technology Group 7
        • XW033CA New Technology Group 10
      • XW033D Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension
        • XW033D6 New Technology Group 6
        • XW033DA New Technology Group 10
      • XW033E Etesevimab Monoclonal Antibody
        • XW033E5 New Technology Group 5
        • XW033E6 New Technology Group 6
      • XW033F Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy
        • XW033F3 New Technology Group 3
        • XW033F5 New Technology Group 5
        • XW033F6 New Technology Group 6
        • XW033FA New Technology Group 10
      • XW033G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
        • XW033G5 New Technology Group 5
        • XW033G6 New Technology Group 6
        • XW033G7 New Technology Group 7
      • XW033H Axicabtagene Ciloleucel Immunotherapy
        • XW033H5 New Technology Group 5
        • XW033H6 New Technology Group 6
        • XW033H7 New Technology Group 7
      • XW033J Tisagenlecleucel Immunotherapy
      • XW033K Sulbactam-Durlobactam
        • XW033K9 New Technology Group 9
      • XW033L Lifileucel Immunotherapy
        • XW033L6 New Technology Group 6
        • XW033L7 New Technology Group 7
      • XW033M Brexucabtagene Autoleucel Immunotherapy
      • XW033N Lisocabtagene Maraleucel Immunotherapy
      • XW033P Glofitamab Antineoplastic
        • XW033P9 New Technology Group 9
      • XW033Q Posoleucel
        • XW033Q5 New Technology Group 5
        • XW033Q9 New Technology Group 9
      • XW033R Rezafungin
      • XW033S Iobenguane I-131 Antineoplastic
        • XW033S5 New Technology Group 5
      • XW033W Caplacizumab
    • XW03 Peripheral Vein